Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy.

Autor: Begré L; Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland.; Graduate School for Health Sciences, University of Bern, Switzerland., Boyd A; Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, The Netherlands.; Stichting hiv monitoring Amsterdam, The Netherlands.; Department of Infectious Diseases, Amsterdam UMC location University of Amsterdam, The Netherlands.; Department of Infectious Diseases, Amsterdam Institute for Infection and Immunity, The Netherlands., Plissonnier ML; Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.; IHU Lyon, Lyon Hepatology Institute, Lyon, France., Testoni B; Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.; IHU Lyon, Lyon Hepatology Institute, Lyon, France., Salazar-Vizcaya L; Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland., Suter-Riniker F; Institute for Infectious Diseases, University of Bern, Switzerland., Scholtès C; Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.; Laboratoire de Virologie, Institut des Agents Infectieux, Hospices Civils de Lyon, France., Béguelin C; Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland., Rockstroh JK; HIV Clinic, Department of Medicine I, University Hospital Bonn, Germany., Günthard HF; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Switzerland., Calmy A; Division of Infectious Diseases, HIV Unit, Geneva University Hospitals, University of Geneva, Switzerland., Cavassini M; Division of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Switzerland., Hirsch HH; Transplantation and Clinical Virology, Department of Biomedicine, University of Basel, Switzerland., Schmid P; Division of Infectious Diseases, Infection Prevention and Travel Medicine, Cantonal Hospital St. Gallen, Switzerland., Bernasconi E; Division of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and University of Southern Switzerland, Lugano, Switzerland., Levrero M; Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.; IHU Lyon, Lyon Hepatology Institute, Lyon, France.; University of Lyon, University Claude Bernard Lyon 1 (UCBL1), Lyon, France.; Department of Hepatology, Hospices Civils de Lyon, Lyon, France., Wandeler G; Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland., Zoulim F; Cancer Research Center of Lyon (CRCL), UMR Inserm U1052 / CNRS 5286, Lyon, France.; IHU Lyon, Lyon Hepatology Institute, Lyon, France.; University of Lyon, University Claude Bernard Lyon 1 (UCBL1), Lyon, France.; Department of Hepatology, Hospices Civils de Lyon, Lyon, France., Rauch A; Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2024 Oct 16; Vol. 230 (4), pp. e954-e963.

CXCR7 genetic variant predicts treatment response of pegylated-interferon α in HBeAg-positive chronic hepatitis B patients.

Autor: Luo M; State Key Laboratory of Organ Failure Research, MOE Key Laboratory of Infectious Diseases Research in South China, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China; The Key Laboratory of Molecular Pathology (Hepatic Diseases) of Guangxi, Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China; Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China., Liang X; State Key Laboratory of Organ Failure Research, MOE Key Laboratory of Infectious Diseases Research in South China, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China., Zhou B; State Key Laboratory of Organ Failure Research, MOE Key Laboratory of Infectious Diseases Research in South China, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China., Hou J; State Key Laboratory of Organ Failure Research, MOE Key Laboratory of Infectious Diseases Research in South China, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address: jlhousmu@163.com., Jiang DK; State Key Laboratory of Organ Failure Research, MOE Key Laboratory of Infectious Diseases Research in South China, Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, China; The Key Laboratory of Molecular Pathology (Hepatic Diseases) of Guangxi, Department of Pathology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China. Electronic address: dekejiang17@smu.edu.cn.

Publikováno v: Antiviral research [Antiviral Res] 2024 Nov; Vol. 231, pp. 106005. Date of Electronic Publication: 2024 Sep 10.

Hepatitis B vaccine responders show higher frequencies of CD8 ⁺ effector memory and central memory T cells compared to non-responders.

Autor: Vakili ME; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran., Mashhadi N; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran., Ataollahi MR; Department of Immunology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran., Meri S; Department of Bacteriology and Immunology and the Translational Immunology Research Program (TRIMM), Helsinki University Hospital, The University of Helsinki and HUSLAB, Helsinki, Finland., Kabelitz D; Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig, Holstein Campus Kiel, Kiel, Germany., Kalantar K; Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.; Department of Bacteriology and Immunology and the Translational Immunology Research Program (TRIMM), Helsinki University Hospital, The University of Helsinki and HUSLAB, Helsinki, Finland.; Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Publikováno v: Scandinavian journal of immunology [Scand J Immunol] 2024 Nov; Vol. 100 (5), pp. e13402. Date of Electronic Publication: 2024 Aug 27.

CRISPR-Cas13b-mediated suppression of HBV replication and protein expression.

Autor: McCoullough LC; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Fareh M; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Hu W; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Sozzi V; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Makhlouf C; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Droungas Y; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Lee CL; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia., Takawy M; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Fabb SA; Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia., Payne TJ; Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia., Pouton CW; Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia., Netter HJ; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Lewin SR; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia., Purcell DF; Department of Microbiology and Immunology, The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Holmes JA; Department of Gastroenterology, St. Vincent's Hospital, Melbourne, Victoria, Australia., Trapani JA; Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia., Littlejohn M; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Revill PA; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. Electronic address: peter.revill@vidrl.org.au.

Publikováno v: Journal of hepatology [J Hepatol] 2024 Nov; Vol. 81 (5), pp. 794-805. Date of Electronic Publication: 2024 May 28.

The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment.

Autor: Zhang W; Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China., Chen J; Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China., Sun W; Department of Infectious Diseases, Ezhou Central Hospital, Ezhou, China., Xie N; Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China., Tian F; Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China., Ruan Q; Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China. ruanqiurong@sina.com., Song J; Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, China. songsingsjx@sina.com.

Publikováno v: Virology journal [Virol J] 2024 Oct 03; Vol. 21 (1), pp. 243. Date of Electronic Publication: 2024 Oct 03.